女性早发Danon病携带者14年管理:家系临床表型与心脏移植疗效分析
单中心回顾性分析1例23岁女性Danon病先证者及其家系,7岁起病表现为非梗阻性肥厚型心肌病,19岁进展为扩张型心肌病,22岁确诊终末期心力衰竭并接受原位心脏移植。基因检测发现LAMP2基因c.459C>A致病性杂合变异,术后随访3年心功能正常。母亲携带相同变异并于29岁接受心脏移植。
要点
- 年轻女性肥厚型心肌病患者应警惕Danon病,早期基因检测有助于确诊。
- Danon病可快速进展为扩张型心肌病和终末期心力衰竭。
- 心脏移植是Danon病终末期患者的有效治疗手段,术后长期疗效显著。
核心结论
- 女性Danon病患者仍可表现出快速进展性心肌病的临床特征。
- 心脏移植是Danon病终末期患者的有效治疗手段,术后长期随访疗效显著。
- 年轻肥厚型心肌病患者应警惕Danon病,早期基因检测有助于明确诊断。
研究设计与样本
- 本研究为单中心回顾性病例分析。
- 选取2009年1月至2024年7月于中国医学科学院阜外医院诊治并接受心脏移植的Danon病先证者1例。
- 回顾性收集先证者及其家系成员的病史、影像学、心电图、实验室、病理及基因检测结果,并定期随访。
主要发现
- 先证者女性,23岁,7岁起病,初期为非梗阻性肥厚型心肌病(左心室壁最厚处29 mm)伴舒张功能减低。
- 19岁时进展为扩张型心肌病(左心室舒张末期内径61 mm,左心室射血分数35%)。
- 22岁确诊终末期心力衰竭(心脏指数2.4 L·min-1·m-2)。
- 基因检测显示携带LAMP2基因c.459C>A(p.Cys153Ter)致病性杂合变异。
- 22岁接受原位心脏移植,术后随访3年心功能维持正常(左心室射血分数>60%)。
临床怎么用
- 对年轻肥厚型心肌病患者应警惕Danon病可能,早期开展基因检测以明确诊断。
- Danon病终末期患者可考虑心脏移植,术后需长期随访评估心功能。
- 家系成员应进行基因筛查,识别携带相同致病变异者。
局限性
- 本研究为单中心回顾性病例分析,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical characteristics, disease progression pattern, genetic variant features, and therapeutic effect of heart transplantation in a family with Danon disease. Methods: This study is a single-center retrospective case analysis. A proband with Danon disease who was diagnosed and treated at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College between January 2009 and July 2024 and underwent heart transplantation was selected. Retrospective data were collected, including medical history, imaging findings (echocardiography, cardiac magnetic resonance), electrocardiogram, laboratory indicators, pathological examination results, and genetic testing results of the proband and her family members. Regular follow-up was conducted to evaluate the patient's disease progression and post-transplant recovery. Results: The proband was a 23-year-old female with an onset age of 7 years. Initially, the patient presented with non-obstructive hypertrophic cardiomyopathy (maximum left ventricular wall thickness: 29 mm) accompanied by reduced diastolic function. At 19 years old, the disease progressed to dilated cardiomyopathy (left ventricular end-diastolic diameter: 61 mm; left ventricular ejection fraction: 35%). At 22 years old, she was diagnosed with end-stage heart failure (cardiac index: 2.4 L·min-1·m-2). Genetic testing revealed that the patient carried a pathogenic heterozygous variant of the LAMP2 gene c.459C>A (p.Cys153Ter). She underwent orthotopic heart transplantation at 22 years old, and during 3 years of post-transplant follow-up, her cardiac function remained normal (left ventricular ejection fraction >60%). The patient's mother carried the same genetic variant and underwent heart transplantation at 29 years old. Conclusion: Despite being female, the Danon disease patient in this case exhibited clinical features of rapidly progressive cardiomyopathy. Heart transplantation is an effective treatment for patients with end-stage Danon disease, with significant long-term therapeutic effects confirmed by post-transplant follow-up. Clinicians should be alert to the possibility of Danon disease in young patients with hypertrophic cardiomyopathy. Early genetic testing helps confirm the diagnosis and provides a basis for clinical intervention. 目的: 探讨一Danon病家系的临床特征、疾病进展规律、基因变异特点及心脏移植治疗效果。 方法: 本研究为单中心回顾性病例分析。选取2009年1月至2024年7月于中国医学科学院阜外医院诊治并接受心脏移植的Danon病先证者1例,回顾性收集先证者及其家系成员的病史资料、影像学检查(超声心动图、心脏磁共振)结果、心电图、实验室指标、病理检查及基因检测结果。通过定期随访评估患者病情进展及心脏移植后的恢复情况。 结果: 先证者女性,23岁,7岁起病。疾病初期表现为非梗阻性肥厚型心肌病(左心室壁最厚处29 mm),伴舒张功能减低。19岁时疾病进展为扩张型心肌病(左心室舒张末期内径61 mm,左心室射血分数35%),22岁确诊终末期心力衰竭(心脏指数2.4 L·min-1·m-2)。基因检测结果显示,患者携带LAMP2基因c.459C>A(p.Cys153Ter)致病性杂合变异。患者于22岁接受原位心脏移植,术后随访3年,心功能维持正常(左心室射血分数>60%)。患者母亲携带相同基因变异,且于29岁时接受心脏移植治疗。 结论: 本例Danon病患者虽为女性,仍表现出快速进展性心肌病的临床特征。心脏移植是Danon病终末期患者的有效治疗手段,术后长期随访结果显示疗效显著。临床中对年轻肥厚型心肌病患者应警惕Danon病可能,早期开展基因检测有助于明确诊断,为临床干预提供依据。.
引用
- Zhao HZ, Sun Y, Zhang ZH, et al. [A 14-year management of an early-onset female Danon disease carrier: analysis of family clinical phenotype and transplant efficacy]. Zhonghua Xin Xue Guan Bing Za Zhi. 2026. PMID: 41688182. doi:10.3760/cma.j.cn112148-20250813-00574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。